| Literature DB >> 32547937 |
Tao Xu1, Yong Yan1, Alexander I Evins2, Zhenyu Gong1, Lei Jiang1, Huaiyu Sun3, Li Cai4, Hongxiang Wang1, Weiqing Li5, Yicheng Lu1, Ming Zhang6, Juxiang Chen1.
Abstract
Objective: Surgical removal of anterior clinoidal meningiomas (ACMs) remains a challenge because of its complicated relationship with surrounding meninges, major arteries and cranial nerves. This study aims to define the meningeal structures around the anterior clinoid process (ACP) and its surgical implications.Entities:
Keywords: anterior clinoid process; anterior clinoidal meningioma; carotid artery; cavernous sinus; classification; meninges; surgical anatomy
Year: 2020 PMID: 32547937 PMCID: PMC7278713 DOI: 10.3389/fonc.2020.00634
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The anterior clinoid process (ACP) and its meningeal coverings. (A) A posterosuperior view of the ACP, showing its four zones (I–IV). (B) A coronal sheet plastination section at the level of the clinoidal segment of the carotid artery (CA). Arrows point the lateral wall of cavernous sinus. (C) is the mirror confocal image of (B). Arrowheads point to the periosteal dura. Arrows point to the meningeal dura. (D) is the higher magnification of the dashed line box of (C), showing the meningeal architecture (single arrow and arrowheads) on the inferolateral surface of the ACP and its relationship with the dural sleeves (double arrows) of the ocular motor (III) and the lateral wall of the cavernous sinus. Double arrowheads point to sagittally orientated meningeal dural fibers, which originated from the tentorium and inserted to the ACP. (E) is from an adjacent section through the tip of the ACP, 3.4 mm posterior to (D), showing the meningeal dural fibrous bundles (arrows) between C4 and C6 segments of the CA. (F) An illustration showing the meningeal architecture of the ACP and its surrounding structures that were mentioned in the previous images. BV, cerebral bridging vein; vp, venous plexus; Sph, sphenoid bone; SphS, sphenoid sinus; TL, temporal lobe; FL, frontal lobe; SAS, subarachnoid space; cranial nerves II, III, IV, V1, V2, and VI; bars = 1 mm.
Classification of anterior clinoidal meningiomas and surgical implications.
| Type I | Superior surface of the ACP | Grow superiorly and laterally to the supraclinoidal space; | Frontal-temporal craniotomy |
| Type IIa | Lateral surface of the ACP | Grow along the lateral wall of cavernous sinus; | Frontal-temporal craniotomy+ Zygomatic osteotomy+/– Anterior clinoidectomy |
| Type IIb | Tip of the ACP | Grow both inside and outside of the cavernous sinus following the meningeal dura near the oculomotor triangle; | Frontal-temporal craniotomy+ Supraorbital osteotomy+ Zygomatic osteotomy+ Anterior clinoidectomy+ Para-cavernous maneuvers |
| Type III | Medial surface of ACP (above the distal dural ring) | Grow medially following the dural ring, diaphragm sellae. | Frontal-temporal craniotomy |
| Type IV | Difficult to be identified | Grow into multiple sellar and parasellar spaces, encasing the surrounding structures. | All the above surgical techniques. Carotid artery control is advocated. The patient may need a surgical plan with possible intentional partial resection to preserve important structures. |
ACP, Anterior Clinoid Process; +, with; +/−, with/without.
Figure 2Classifications of anterior clinoidal meningiomas (ACMs) based on meningeal anatomy of the anterior clinoid process (ACP). Each horizontal panel represents an illustration of coronal sectional view, a preoperative and postoperative MR images of a type of ACMs. (A–C) Type I ACMs originate from the superior surface of the ACP. Note that the tumor may invade into the optic canal following the falciform ligament. (D–F) Type IIa ACMs originate from the lateral surface of ACP. They “attach” and “push” rather than invade the cavernous sinus because of the thick and multilayer meningeal on the lateral wall of cavernous sinus. (G–I) Type IIb ACMs originate from the tip of the ACP and grow both inside and outside of the cavernous sinus following the meningeal dura near the oculomotor triangle. (J–L) Type III ACMs that originated from the medial surface of ACP; they could affect the distal dural ring and wrap the ICA from the very beginning. (M–O) Type IV ACMs that extend to multiple directions following the meninges.
Clinicopathological characteristics of anterior clinoidal meningioma patients.
| Range | 27–76 | 33–73 | 27–76 | 27–73 | 33–60 | 38–64 |
| Mean ± SD | 53.66 ± 10.82 | 55.95 ± 9.68 | 57.31 ± 12.77 | 55.83 ± 12.04 | 46.77 ± 8.42 | 47.75 ± 6.78 |
| Male | 45 (34.4%) | 22 (40.0%) | 8 (30.8%) | 6 (50.0%) | 8 (36.4%) | 1 (6.3%) |
| Female | 86 (65.6%) | 33 (60.0%) | 18 (69.2%) | 6 (50.0%) | 14 (63.6%) | 15 (93.7%) |
| Vision decrease | 57 (43.5%) | 25 (45.5%) | 1 (3.8%) | 3 (25.0%) | 16 (72.7%) | 12 (75.0%) |
| Headache | 45 (34.4%) | 12 (21.8%) | 11 (42.3%) | 4 (33.3%) | 3 (13.7%) | 15 (93.7%) |
| Dizziness | 32 (24.4%) | 11 (20.0%) | 8 (30.8%) | 4 (33.3%) | 3 (13.7%) | 6 (37.5%) |
| Incidental finding | 11 (8.4%) | 5 (9.1%) | 3 (11.5%) | 1 (8.3%) | 2 (9.1%) | 0 (0%) |
| Seizure | 7 (5.3%) | 0 (0%) | 3 (11.5%) | 3 (25.0%) | 0 (0%) | 1 (6.2%) |
| Limb weakness | 6 (4.6%) | 1 (1.8%) | 2 (7.7%) | 0 (0%) | 0 (0%) | 3 (18.8%) |
| Diplopia | 4 (3.1%) | 0 (0%) | 0 (0%) | 2 (16.7%) | 0 (0%) | 2 (12.5%) |
| Ptosis | 3 (2.3%) | 0 (0%) | 0 (0%) | 1 (8.3%) | 0 (0%) | 2 (12.5%) |
| ≥3 cm | 108 (82.4%) | 40 (72.7%) | 23 (88.5%) | 12 (100%) | 17 (77.3%) | 16 (100%) |
| <3 cm | 23 (17.6%) | 15 (27.3%) | 3 (11.5%) | 0 (0%) | 5 (22.7%) | 0 (0%) |
| Grade 1–2 | 88 (67.2%) | 47 (85.5%) | 24 (92.3%) | 0 (0%) | 12 (54.5%) | 5 (31.3%) |
| Grade 3–4 | 43 (32.8%) | 8 (14.5%) | 2 (7.7%) | 12 (100%) | 10 (45.5%) | 11 (68.7%) |
| WHO grade I | 120 (91.6%) | 51 (92.7%) | 25 (96.2%) | 11 (91.7%) | 20 (90.9%) | 13 (81.3%) |
| WHO grade II | 10 (7.6%) | 4 (7.3%) | 1 (3.8%) | 1 (8.3%) | 2 (9.1%) | 2 (12.5%) |
| WHO grade III | 1 (0.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (6.2%) |
| <5% | 73 (81.1%) | 32 (86.5%) | 18 (94.7%) | 8 (72.7%) | 13 (76.5%) | 2 (33.3%) |
| 5–10% | 15 (16.7%) | 5 (13.5%) | 1 (5.3%) | 2 (18.2%) | 4 (23.5%) | 3 (50%) |
| >10% | 2 (2.2%) | 0 (0%) | 0 (0%) | 1 (10.1%) | 0 (0%) | 1 (16.7%) |
Univariate and multivariate analysis for factors associated with extent of resection of ACMs.
| Age (years) | 0.326 | 0.729 | |||
| <40 | 1.000 | 1.000 | 1.348 | 0.774 | 0.175-9.366 |
| 40–60 | 0.552 | 0.171 | 0.735 | 0.639 | 0.202-2.671 |
| >60 | Reference | Reference | Reference | Reference | |
| Type of ACMs | <0.001 | 0.024 | |||
| I | 12.925 | <0.001 | 4.769 | 0.065 | 0.909–25.017 |
| IIa | 26.400 | <0.001 | 13.314 | 0.014 | 1.684–105.270 |
| IIb | 0.000 | 0.999 | 0.000 | 0.999 | 0 |
| III | 2.640 | 0.159 | 0.714 | 0.726 | 0.108–4.705 |
| IV | Reference | Reference | Reference | Reference | Reference |
| Vision decrease (yes vs. no) | 0.475 | 0.049 | 0.800 | 0.703 | 0.254–2.517 |
| Headache (yes vs. no) | 0.456 | 0.042 | 0.419 | 0.207 | 0.108–1.618 |
| Dizziness (yes vs. no) | 1.641 | 0.281 | 1.101 | 0.883 | 0.306–3.959 |
| Tumor diameter (<3 cm vs. ≥3 cm) | 0.071 | 0.011 | 0.075 | 0.025 | 0.008–0.724 |
| Gender (female vs. male) | 0.966 | 0.929 | 0.784 | 0.671 | 0.2552.408 |
Statistically significant.
Figure 3Two cases with anterior clinoidal meningiomas (ACMs) that experienced intraoperative rupture of internal carotid artery (ICA). (A) Preoperative coronal MRI showed a type I ACM, which involved the supraclinoidal part of the left ICA. (B) Postoperative coronal MRI showed gross-total resection of tumor, with a small infarction near the left side lateral ventricle, indicating the occlusion of perforators supplying the head of the caudle nuclei. (C) Postoperative angiography showed complete occlusion of the left ICA. (D,E) Preoperative CT angiography showed a type III ACM, which engulfs the bifurcation of the left ICA. (F) Postoperative CT angiography showed patent branches of the ICA with gross total removal of the tumor.
Literature review of recently published papers of anterior clinoidal meningiomas.
| Al-Mefty. ( | 24 | 57 | 83.3 | 25 | 12.5 | Pterional/subfrontal/orbitocranial | NA |
| Kleinpeter Böck ( | 31 | NA | 77.4 | NA | NA | NA | NA |
| Risi et al. ( | 34 | 22.8 | 58.8 | 32 | 21 | Extended pterional | NA |
| Puzzilli et al. ( | 33 | 53.7 | 54.5 | 33.3 | 15.2 | Pterional | WHO I, |
| Goel et al. ( | 60 | 26 | 70.0 | 69.1 | 1.6 | Basal frontotemporal/orbitozygomatic | NA |
| Nakamura et al. ( | 108 | 79 | 42.6 | 46.7 | 20.3 | Pterional/frontolateral | WHO I, |
| Russell et al. ( | 35 | 153.6 | 68.6 | 63 | 9 | Pterional | NA |
| Cui et al. ( | 26 | 22.3 | 61.5 | 61.5 | 0 | Orbitozygomatic | NA |
| Pamir et al. ( | 43 | 39 | 90.7 | 84.6 | 11.7 | Pterional | WHO I, |
| Sade and Lee ( | 52 | NA | 71.2 | 77 | NA | Pterional + posterolateral orbitotomy + clinoidectomy | NA |
| Bassiouni et al. ( | 106 | 83 | 57.5 | 45.6 | 25.3 | Pterional + optic nerve decompression + subdural clinoidectomy | WHO I, |
| Romani et al. ( | 73 | 36 | 78.1 | 28.2 | 4.1 | Lateral supraorbital | WHO I, |
| Nagata et al. ( | 23 | 49.2 | 39.1 | 43.5 | 4.3 | Pterional/orbitozygomatic | NA |
| Attia et al. ( | 22 | 56 | 59.1 | 66.7 | 13.6 | Pterional/frontoorbital/orbitozygomatic | WHO I, |
| Czernicki et al. ( | 30 | 83 | 63.3 | 43.8 | 36.8 | Fronto-orbitozygomatic | WHO I, |
| Sughrue et al. ( | 29 | 90 | 20.7 | 17.2 | 6.9 | Frontotemporal/orbitozygomatic | WHO I, |
| Nanda et al. ( | 36 | 33 | 75.0 | 28 | 11.1 | Pterional/orbitozygomatic | WHO I, |
| Kim et al. ( | 59 | 54.1 | 64.4 | NA | 18.6 | Orbitocranial or orbitozygomatic/extended pterional/subfrontal | NA |
| 131 | 76 | 67.2 | 52.6 | 11.4 | Frontotemporal craniotomy with individualized skull base techniques | WHO I, |
No., Number; NA, Not Applicable.
Figure 4Summary of literature on the extent of resection, visual function and tumor progression of ACMs. (A) A total of 18 studies (excluding the present study) reported the extent of resection of ACMs, ranging from 20.7–90.7%. (B) The rate of visual function improvement among 16 studies. 37.5% of studies (6/16) revealed improvements in visual function in more than 50% of patients. (C) The progression/recurrence rate varies from 0–36.8% in 16 studies.